Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation
by Krista Conger,Stanford UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDCAR-T cell therapy, which
Updated on: July 17,2024
0

Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation
by Krista Conger,Stanford UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDCAR-T cell therapy, which
Updated on:July 17,2024
0
